Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Gallo Center Scientists Identify Potential New Mechanism for Treating Problem Drinking

Published: Monday, February 25, 2013
Last Updated: Monday, February 25, 2013
Bookmark and Share
Researchers identified a potential new approach for reducing problem drinking: a new family of drugs with the ability to manipulate DNA structure without changing it.

The drugs, already approved for human use for other indications, reduced drinking and alcohol-seeking behavior in pre-clinical models — mice and rats trained to drink large quantities of alcohol.

The animals in the study, which was published today in the advance online edition of Translational Psychiatry, were trained to mimic so-called “problem drinkers,” not-yet-full-blown alcoholics, said senior author Dorit Ron, PhD, a Gallo Center investigator and a professor of neurology at UCSF.

“They consumed large quantities of alcohol and drank in binges, but were not yet physically dependent on alcohol,” she said. “In humans, these drugs could represent a promising new direction in preventing drinkers from going on to become fully addicted.”

The drugs, which inhibit enzymes called DNMT and HDAC, are currently being used to treat several types of cancer and show promise as medications for the treatment of mood disorders.

The study presents “a potential new mechanism to control excessive drinking,” said Ron.

The drugs act by modifying the structure of chromatin – a combination of DNA and proteins known as histones -- without affecting the composition of DNA itself, Ron said.

“Normally, changes on the DNA sequence called methylation lead to tightening of the chromatin structure, which prevents the expression of certain genes,” she said. “Conversely, a change in histones called acetylation leads to the opening of the DNA structure, allowing certain genes to be expressed.” DNMT inhibitors, which prevent methylation, and HDAC inhibitors, which promote acetylation, both act to loosen DNA structure, which in turn allows gene expression.

In the study, Ron and her research team trained mice to drink a solution of 20 percent alcohol. Mice that were given a DNMT inhibitor called 5-AzaC or HDAC inhibitors drank significantly less than mice that were not given the DNMT inhibitor.

Rats were also trained to self-administer drinks of alcohol by pressing a lever. Rats given SAHA, an HDAC inhibitor, showed significantly less alcohol-seeking behavior.

Importantly, in both mice and rats, the consumption of water, saccharine solution and sugar solution remained unchanged. “This means that these drugs specifically target alcohol without affecting the pleasure centers of the brain,” said Ron. “For people who have problems with alcohol, this would be a real improvement over current abuse medications, which suppress pleasure in general, leading to problems with compliance.”

Ron noted that alcohol use disorders represent a significant threat to public health worldwide, causing or being associated with a wide variety of physical and psychiatric illnesses. She called the study “an important example of pre-clinical, translational research, where findings in basic science lead straight to the possibility of clinical studies.”

Co-authors of the study are Vincent Warnault, PhD, and Emmanuel Darcq, PhD, of the Gallo Center and UCSF; Amir Levine, MD, of Columbia University; and Segev Barak, PhD, who was with Gallo and UCSF at the time of the study.

The study was supported by funds from the National Institutes of Health and the State of California through UCSF.

The UCSF-affiliated Ernest Gallo Clinic and Research Center is one of the world’s preeminent academic centers for the study of the biological basis of alcohol and substance use disorders. Gallo Center discoveries of potential molecular targets for the development of therapeutic medications are extended through preclinical and proof-of-concept clinical studies.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos